Lucy Therapeutics
Allen brings his extensive drug discovery research expertise to Lucy Therapeutics, having most recently served as Senior Director of Medicinal Chemistry at Remix Therapeutics and Director of Exploratory Research at Sage Therapeutics. He held senior positions at Turing Pharmaceuticals AG, Lundbeck and Memory Pharmaceuticals, moving drugs from early metabolism and PK studies to regulatory filings as promising INDs.
This person is not in any teams
Lucy Therapeutics
Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.